Literature DB >> 22139886

Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study.

Sanjay Dixit1, Francis E Marchlinski, David Lin, David J Callans, Rupa Bala, Michael P Riley, Fermin C Garcia, Mathew D Hutchinson, Sarah J Ratcliffe, Joshua M Cooper, Ralph J Verdino, Vickas V Patel, Erica S Zado, Nancy R Cash, Tony Killian, Todd T Tomson, Edward P Gerstenfeld.   

Abstract

BACKGROUND: The single-procedure efficacy of pulmonary vein isolation (PVI) is less than optimal in patients with persistent atrial fibrillation (AF). Adjunctive techniques have been developed to enhance single-procedure efficacy in these patients. We conducted a study to compare 3 ablation strategies in patients with persistent AF. METHODS AND
RESULTS: Subjects were randomized as follows: arm 1, PVI + ablation of non-PV triggers identified using a stimulation protocol (standard approach); arm 2, standard approach + empirical ablation at common non-PV AF trigger sites (mitral annulus, fossa ovalis, eustachian ridge, crista terminalis, and superior vena cava); or arm 3, standard approach + ablation of left atrial complex fractionated electrogram sites. Patients were seen at 6 weeks, 6 months, and 1 year; transtelephonic monitoring was performed at each visit. Antiarrhythmic drugs were discontinued at 3 to 6 months. The primary study end point was freedom from atrial arrhythmias off antiarrhythmic drugs at 1 year after a single-ablation procedure. A total of 156 patients (aged 59±9 years; 136 males; AF duration, 47±50 months) participated (arm 1, 55 patients; arm 2, 50 patients; arm 3, 51 patients). Procedural outcomes (procedure, fluoroscopy, and PVI times) were comparable between the 3 arms. More lesions were required to target non-PV trigger sites than a complex fractionated electrogram (33±9 versus 22±9; P<0.001). The primary end point was achieved in 71 patients and was worse in arm 3 (29%) compared with arm 1 (49%; P=0.04) and arm 2 (58%; P=0.004).
CONCLUSIONS: These data suggest that additional substrate modification beyond PVI does not improve single-procedure efficacy in patients with persistent AF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00379301.

Entities:  

Mesh:

Year:  2011        PMID: 22139886     DOI: 10.1161/CIRCEP.111.966226

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  61 in total

1.  A Decade of CFAE Mapping: Still Seeking More Specific Tools to Identify Sources and Substrate of Persistent Atrial Fibrillation.

Authors:  Amir S Jadidi; Thomas Arentz
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-08

Review 2.  Approaches to Catheter Ablation of Nonparoxysmal Atrial Fibrillation.

Authors:  Jackson J Liang; Daniele Muser; Pasquale Santangeli
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

Review 3.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

4.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane
Journal:  Heart Rhythm       Date:  2017-05-12       Impact factor: 6.343

5.  Catheter ablation of persistent atrial fibrillation: The importance of substrate modification.

Authors:  Konstantinos P Letsas; Michael Efremidis; Nikolaos P Sgouros; Konstantinos Vlachos; Dimitrios Asvestas; Antonios Sideris
Journal:  World J Cardiol       Date:  2015-03-26

6.  Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation).

Authors:  Sanjiv M Narayan; Tina Baykaner; Paul Clopton; Amir Schricker; Gautam G Lalani; David E Krummen; Kalyanam Shivkumar; John M Miller
Journal:  J Am Coll Cardiol       Date:  2014-03-13       Impact factor: 24.094

7.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; José Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  Heart Rhythm       Date:  2012-03-01       Impact factor: 6.343

8.  Reduction of radiation exposure during ablation of atrial fibrillation.

Authors:  Ralph Schneider; Jörg Lauschke; Cindy Schneider; Tina Tischer; Aenne Glass; Dietmar Bänsch
Journal:  Herz       Date:  2015-05-20       Impact factor: 1.443

9.  Outcomes after cryoballoon or radiofrequency ablation for persistent atrial fibrillation: a multicentric propensity-score matched study.

Authors:  Serge Boveda; Rui Providência; Pascal Defaye; Dominique Pavin; Jean-Pierre Cebron; Frederic Anselme; Franck Halimi; Ziad Khoueiry; Nicolas Combes; Stephane Combes; Sophie Jacob; Jean-Paul Albenque; Pedro Sousa
Journal:  J Interv Card Electrophysiol       Date:  2016-05-18       Impact factor: 1.900

Review 10.  Ablation of long-standing persistent atrial fibrillation.

Authors:  Behram P Mody; Anoshia Raza; Jason Jacobson; Sei Iwai; Daniel Frenkel; Rhadames Rojas; Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.